AstraZeneca to sell China-developed lung cancer drug in the US
AstraZeneca said on Thursday that it would begin selling sunvozertinib in the United States under the brand name Zegfrovy after securing worldwide rights from China’s Dizal Pharmaceutical. The targeted lung-cancer drug had received US FDA accelerated approval…
